Clinical Trial Update: Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating induction PD-1 blockade with nivolumab in patients with surgically complete resectable mismatch repair-deficient endometrial c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Yonsei University | Conditions: Endometrial Neoplasms, Endometrial Cancer | Phase 2 | Status: RECRUITING